H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Regenxbio (RGNX) to $36 from $40 and keeps a Buy rating on the shares after the company reported the first functional data from the Phase 1/2 trial of RGX-202 in Duchenne muscular dystrophy. In view of the latest reported sales of Elevidys, the firm toned down its projected peak sales of RGX-202.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- 3 Best Stocks to Buy Now, 11/21/2024, According to Top Analysts
- Biotech Alert: Searches spiking for these stocks today
- 3 Best Stocks to Buy Now, 11/19/2024, According to Top Analysts
- Regenxbio price target raised to $38 from $34 at Leerink
- Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz